{"entity":{"id":"nct06504147","kind":"trial","name":"A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery","aka":[],"tldr":"A phase 2 trial of Radspherin in ovarian cancer, run by Oncoinvent Solutions AS, now recruiting.","summary":"A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery is a phase 2 interventional study registered as NCT06504147 by Oncoinvent Solutions AS, with 114 participants planned, started 2024-06-15 and due to reach its primary completion in 2028-02-29. Interventions recorded: Radspherin.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06504147","url":"https://clinicaltrials.gov/study/NCT06504147"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["ovarian","high-grade-serous-ovarian-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06504147","phase":"2","setting":"A Phase 2, Randomised, Open Label, Multicentre Study of an Intraperitoneal α-emitting Radionuclide Therapy (Radspherin®) in Patients With Primary Advanced High-grade Serous or High-grade Endometrioid Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient and Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery","sponsor":"Oncoinvent Solutions AS","participation":[{"nct":"NCT06504147","source":"https://clinicaltrials.gov/study/NCT06504147","fetchedAt":"2026-10-07T16:54:45.035Z","studySha256":"bfc5966aea758c06fa6fc1dac0feee21490a9644838d7b058e07dd29b90bdccf","overallStatus":"RECRUITING","lastUpdatePosted":"2026-05-20","leadSponsor":"Oncoinvent Solutions AS","collaboratorCount":0,"minimumAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"hasEligibility":true,"enrolment":114,"enrolmentType":"ESTIMATED","siteCount":10,"recruitingSiteCount":10,"countries":["Belgium","Italy","Norway","Spain","United Kingdom","United States"]}],"started":"2024-06-15","startedType":"actual","enrolled":114,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06504147/","neighbours":{"cancer":[{"id":"high-grade-serous-ovarian-cancer","kind":"cancer","name":"High-grade serous ovarian cancer","route":"/cancers/high-grade-serous-ovarian-cancer/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}]}}